Halozyme Therapeutics, Inc. (HALO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 10:14AM EDT. Market open.
| Previous close | 43.84 |
| Open | 44.08 |
| Bid | 43.75 x 400 |
| Ask | 43.97 x 200 |
| Day's range | 43.68 - 44.21 |
| 52-week range | 31.86 - 45.00 |
| Volume | |
| Avg. volume | 1,025,769 |
| Market cap | 5.582B |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | 18.20 |
| EPS (TTM) | 2.41 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 51.78 |
Insider MonkeyHalozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript May 7, 2024 Halozyme Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. My name is [Perla] (ph), and I’ll be your conference operator today. […]
ZacksHalozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates
Halozyme (HALO) reports mixed first-quarter 2024 earnings. The company maintains revenue guidance for 2024.
PR NewswireHalozyme to Participate in Upcoming Investor Conferences
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences:
© 2024 Yahoo. All rights reserved.